Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has shown a 4.40% increase over the past month and a 0.19% increase over the past three months, while it has decreased by 0.01% year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (11.76%), United Imaging (10.54%), Aibo Medical (7.72%), Yirui Technology (6.34%), Shengxiang Biology (5.03%), Nanwei Medical (5.02%), Xinmai Medical (4.57%), Haier Biomedical (4.39%), Yahui Long (3.59%), and Aohua Endoscopy (3.38%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% market share [1] - The industry composition of the index holdings includes 46.02% in medical consumables, 33.17% in medical devices, and 20.81% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which are fixed until the next scheduled adjustment unless a special situation arises [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be processed according to the calculation and maintenance guidelines [2]

5月6日，心脉医疗今日收盘86.03元，上涨1.85%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到23.70倍，总市值106.04亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.90倍，行业中值36.41倍，心脉医疗排 名第52位。 股东方面，截至2025年3月31日，心脉医疗股东户数18176户，较上次增加523户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)52心脉医疗23.7021.122.76106.04亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-417.99-494.372.2989.45亿4博晖创新-329.61523.043.5248.36亿5爱朋 医疗-325.82247.533.9226.73亿6硕世生物-125.93-1840.221.1336.84亿7奥精医疗-117.01-171.501.5421 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-022 关于以集中竞价交易方式第二期回购股份的进展公告 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，应当在每个月的前 3 个交易日内公告截至上月末 的回购进展情况，现将公司第二期回购方案进展情况公告如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日（第二期） | 2024/10/30 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限（第二期） | 年 月 2024 10 28 10 | 日~2025 | 年 | 月 | 27 | 日 | | 预计回购金额（第二期） | 10,000万元~20,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | 累计已回购股数（第二期） | □为维护公司价 ...

截至2025年4月30日收盘，心脉医疗(688016)报收于84.47元，上涨0.86%，换手率0.92%，成交量1.14万 手，成交额9623.16万元。 当日关注点 交易信息汇总 4月30日心脉医疗的资金流向情况如下：主力资金净流出258.91万元，占总成交额2.69%；游资资金净流 入313.36万元，占总成交额3.26%；散户资金净流出54.45万元，占总成交额0.57%。 心脉医疗近日披露了最新的股东户数变动情况。截至2025年3月31日，公司股东户数为1.82万户，较2月 28日增加了523户，增幅为2.96%。同时，户均持股数量从上期的6982股减少至6782股，户均持股市值 为61.11万元。 交易信息汇总: 主力资金净流出258.91万元，占总成交额2.69%；游资资金净流入313.36万元，占 总成交额3.26%。 股本股东变化: 截至2025年3月31日公司股东户数为1.82万户，较2月28日增加523户，增幅为 2.96%。 业绩披露要点: 心脉医疗2025年一季度主营收入3.32亿元，同比下降7.23%；归母净利润1.3亿元， 同比下降29.66%。 业绩披露要点 心脉医疗2025年 ...

2025年4月30日，心脉医疗(688016.SH)发布2025年第一季报。截至2025年4月30日，共有10个机构投资 者披露持有心脉医疗A股股份，合计持股量达5634.34万股，占心脉医疗总股本的45.71%。其中，前十 大机构投资者包括MicroPort Endovascular CHINA Corp. Limited、中国银行股份有限公司-华宝中证医疗 交易型开放式指数证券投资基金、全国社保基金四一三组合、微创投资控股有限公司、北京熙诚金睿股 权投资基金管理有限公司-北京新动力股权投资基金(有限合伙)、香港中央结算有限公司、招商银行股份 有限公司-南方中证1000交易型开放式指数证券投资基金、中国工商银行股份有限公司-博时上证科创板 100交易型开放式指数证券投资基金、工银专精特新混合A、广发集瑞债券A，前十大机构投资者合计持 股比例达45.71%。相较于上一季度，前十大机构持股比例合计下跌了1.80个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即工银专精特新混合A，持股增加占比小 幅上涨。本期较上一季度持股减少的公募基金共计2个，包括博时科创100ETF、南方中证1000ETF， ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant price increase in the next 6-12 months [5]. Core Insights - The company reported a revenue of 332 million yuan in Q1 2025, a year-on-year decrease of 7%, and a net profit attributable to shareholders of 130 million yuan, down 30% year-on-year [2]. - The domestic market is facing short-term pressure due to changes in the market environment, leading to adjustments in product pricing and promotional strategies, while the overseas market is expanding rapidly with a sales revenue growth of over 93% year-on-year [3]. - The company has set ambitious growth targets in its employee stock ownership plan, aiming for a net profit of no less than 600 million yuan in 2025, reflecting confidence in future operations [4]. Summary by Sections Performance Overview - In Q1 2025, the company achieved a revenue of 332 million yuan, a decrease of 7% year-on-year, and a net profit of 130 million yuan, down 30% year-on-year [2]. Operational Analysis - The domestic market is under pressure, but the company maintains a leading market share in domestic active artery intervention products and is expanding its market coverage for peripheral vascular intervention products. The overseas market has seen a significant increase in sales, with new registrations in three countries and over 100 total overseas product registrations [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 606 million yuan, 794 million yuan, and 965 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 21%, 31%, and 22% [5].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant price increase in the next 6-12 months [5]. Core Insights - The company reported a revenue of 332 million yuan in Q1 2025, a year-on-year decrease of 7%, and a net profit attributable to shareholders of 130 million yuan, down 30% year-on-year [2]. - The domestic market is facing short-term pressure due to changes in the market environment, leading to adjustments in product pricing and promotional strategies, while the overseas market is expanding rapidly with a sales revenue growth of over 93% year-on-year [3]. - The company has set ambitious growth targets in its employee stock ownership plan, aiming for a net profit of no less than 600 million yuan in 2025, reflecting confidence in future operations [4]. Summary by Sections Performance Overview - In Q1 2025, the company achieved a revenue of 332 million yuan, a decrease of 7% year-on-year, and a net profit of 130 million yuan, down 30% year-on-year [2]. Operational Analysis - The domestic market is under pressure, but the company maintains a leading market share in domestic active artery intervention products and is expanding its market coverage for peripheral vascular intervention products. The overseas market has seen a significant increase in sales, with new registrations in three countries and over 100 total overseas product registrations [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of 606 million yuan, 794 million yuan, and 965 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 21%, 31%, and 22% [5].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688016 证券简称：心脉医疗 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...

上海微创心脉医疗科技（集团）股份有限公司 舆情管理制度 上海微创心脉医疗科技（集团） 股份有限公司 舆情管理制度 二零二五年四月 1 上海微创心脉医疗科技（集团）股份有限公司 舆情管理制度 上海微创心脉医疗科技(集团)股份有限公司 舆情管理制度 第一章 总则 （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品种交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易价格变动 的负面舆情； （二）一般舆情：指除重大舆情之外的其他舆情。 第二章 舆情管理的组织体系和工作职责 第一条 为提高上海微创心脉医疗科技（集团）股份有限公司（以下简称"公 司"）应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类 舆情对公司股价、商业信誉及正常生产经营活动造成的影响，切实保护投资者合法 权益，根据相关法律法规、规范性文件及《上海微创心脉医疗科 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 332,189,385.86, a decrease of 7.23% compared to CNY 358,081,405.15 in the same period last year[4] - Net profit attributable to shareholders was CNY 129,636,898.33, down 29.66% from CNY 184,296,095.55 year-on-year[4] - Basic and diluted earnings per share decreased by 30.00% to CNY 1.05 from CNY 1.50 in the previous year[4] - The company's retained earnings rose to ¥1,214,597,510.58 in Q1 2025, up from ¥1,084,960,612.25 in Q1 2024[17] - The company reported a total comprehensive income of ¥124,733,344.22 in Q1 2025, down from ¥182,831,010.57 in Q1 2024[20] Cash Flow - The net cash flow from operating activities decreased by 81.11%, amounting to CNY 40,027,784.30 compared to CNY 211,948,663.78 in the previous year[4] - Cash inflow from operating activities in Q1 2025 was ¥190,732,776.15, a decline of 52.9% from ¥405,086,857.23 in Q1 2024[20] - The net cash flow from operating activities was $40,027,784.30, a significant decrease from $211,948,663.78 in the previous period, reflecting a decline of approximately 81%[21] - The net increase in cash and cash equivalents was -$1,080,353,621.70, an improvement from -$1,493,736,045.88, indicating a reduction in cash outflow of approximately 27.7%[21] - The ending balance of cash and cash equivalents was $978,477,623.44, down from $1,459,364,476.35, representing a decrease of about 33%[21] Assets and Liabilities - The total assets increased by 4.04% to CNY 4,464,876,823.41 from CNY 4,291,597,451.31 at the end of the previous year[5] - The company's cash and cash equivalents decreased to RMB 1,085,676,371.90 from RMB 2,170,604,749.23, representing a decline of about 50%[14] - Accounts receivable increased significantly to RMB 355,333,176.48 from RMB 209,761,864.13, marking a rise of approximately 69.5%[14] - The total current liabilities rose to RMB 458,518,305.05 from RMB 339,038,781.50, indicating an increase of around 35.3%[16] - The total liabilities of the company reached RMB 580,321,010.96, up from RMB 469,125,424.12, which is an increase of about 23.7%[16] Research and Development - Research and development expenses totaled CNY 29,051,147.32, a reduction of 38.37% from CNY 47,137,794.16, representing 8.75% of operating revenue[5] - Research and development expenses decreased to ¥15,941,366.59 in Q1 2025, down 31.0% from ¥23,190,117.20 in Q1 2024[18] Market Strategy - The company plans to focus on accelerating market access and promotion of aortic and peripheral interventional products in Europe, Latin America, and Asia-Pacific in 2025[9] - Six products are expected to obtain regulatory approval in 2025, with several others anticipated to complete registration or clinical trials[9] Shareholder Actions - The company repurchased a total of 1,952,089 shares, accounting for 1.58% of the total share capital, with a total expenditure of RMB 191,549,546.27[12][13] - The highest repurchase price during the first phase was RMB 103.96 per share, while the second phase saw a peak of RMB 119.82 per share[13] Accounting Changes - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[22]